Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 7 of 15
Jul 18, 2026The latest funding round for Juno Bio highlights increasing investor focus on women's health and the microbiome’s role in wellness. This investment aims to accelerate research and broaden access to diagnostics and therapeutics targeting vaginal health, an area historically underserved within life sciences.
Jul 16, 2026The first half of 2026 marks a pivotal change in digital health investment trends, where the dominance of AI as a differentiator is giving way to a new era defined by deep healthcare knowledge and sector expertise. Investors and founders alike are rethinking what constitutes a sustainable competitive moat in a crowded digital health marketplace.
Jul 11, 2026With fresh capital, Handspring aims to deliver scalable solutions for children’s mental health, matching patients to the right level of care and avoiding unnecessary overuse of intensive, expensive options. This funding round marks a significant step forward in addressing mismatches in mental health care and expanding access nationwide.
Jul 10, 2026IKS Health’s $557 million deal to acquire TruBridge underscores its strategy to reinforce its position in healthcare technology by integrating rural-focused EHR and revenue cycle management into an expanding AI-enabled platform. This analysis explores the implications for healthcare delivery, technology infrastructure, and the competitive landscape.
Jul 8, 2026M&A activity picks up pace as Vertex Pharmaceuticals leads the way in large-scale consolidation, with industry observers noting FDA’s continued steady output amid leadership turmoil. Meanwhile, IPOs and venture investment favor established, derisked biotechs; newcomers compete in a risk-averse landscape.
Jul 7, 2026Private equity’s involvement in healthcare has long generated controversy and debate, focused traditionally on for-profit hospital and provider acquisitions. However, a new trend is drawing attention: joint ventures between private equity firms and nonprofit health systems. As this lesser-known strategy expands, questions arise about financial motivations, patient outcomes, and the degree of regulatory oversight required to safeguard the public interest.
Jun 28, 2026Before allocating ever-larger sums to healthcare, policymakers, payers, and the public must grapple with measuring value—not just output. This debate centers on determining how much system capacity is needed, which outcomes justify investment, and how to align funding with real, measurable improvements in health.
Jun 24, 2026Serapha Bio’s $230 million reverse merger with Boundless Bio marks a significant evolution in biotech dealmaking, enabling the new entity to pursue advanced gene editing for alpha-1 antitrypsin deficiency. The combined company, holding both a robust war chest and proprietary technology sourced from China, signals both the globalization and financial innovation now reshaping the biotech industry.
Jun 24, 2026Digital health startup Cadence’s latest funding round brings its valuation to $1.23 billion, marking a significant milestone in the movement toward automated, data-driven chronic care. The platform’s integration with major health systems signals a broader shift in how ongoing conditions, such as heart failure, hypertension, and diabetes, are managed beyond clinical settings.
Jun 17, 2026InStride’s successful $30 million funding round highlights intensifying demand for pediatric mental health solutions across the United States. The investment signals growing recognition among venture capital and strategic investors of the need for scalable, technology-enabled behavioral health platforms for young patients.
Jun 9, 2026In an era marked by an industry-wide cash crunch and investor wariness, Parabilis Medicines’ ambitious IPO plan, now upsized to potentially $637 million, stands out. This development represents both a test of market appetite and a signal of ongoing interest in well-positioned biotech innovators, even as broader sector health remains under scrutiny.
Jun 5, 2026Hydrocephalus treatment is on the cusp of transformation with CereVasc’s minimally invasive eShunt system. The recent $85 million Series C funding round will support pivotal trials and regulatory submissions aimed at providing patients safer and more effective therapeutic options than conventional brain shunts.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.